The largest database of trusted experimental protocols
> Disorders > Disease or Syndrome > Hydrocephalus, Normal Pressure

Hydrocephalus, Normal Pressure

Hydrocephalus, Normal Pressure is a condition characterized by an abnormal accumulation of cerebrospinal fluid within the ventricles of the brain, resulting in increased intracranial pressure without ventricular enlargement.
This can lead to a variety of neurological symptoms, including cognitive impairment, gait disturbances, and urinary incontinence.
Accurate diagnosis and effective management of this condition are crucial, as it can be a treatable cause of dementia.
Researchers can leverage the power of AI-driven protocol comparisons through PubCompare.ai to optimize their studies, enhance reproducibility, and improve the accuracy of their hydrocephalus and normal pressure research.

Most cited protocols related to «Hydrocephalus, Normal Pressure»

Around 21,000 individuals across the cohorts have been typed using Metabochip (see Table 4), a genotyping platform consisting of ∼200,000 SNPs, which cover the loci identified by GWAS in cardiometabolic diseases, and rare variants from the 1000 Genomes Project [23] (link). This will be supplemented by SNP data from a whole genome array in the 1958 Birth Cohort, the 50 k HumanCVD Beadchip [37] (link) in WHII and BWHHS, and prior candidate and GWAS replication work in all studies. The NPHS-II, EHDPS and AAAT studies are available for new bespoke genotyping e.g. to validate associations from UCLEB samples genotyped by Metabochip. This will yield a powerful aggregate dataset rich in genetic and phenotypic detail.
Duplicate samples have been genotyped to compute the error rate. Initial quality control analysis on genotyped data identified any problem samples that have been subsequently excluded in further analysis. These included: checks for discordance between reported and genetically-determined ethnicity, replicate concordance, sample mix-up (unknown duplicates and comparison to previously genotyped data where available), gender ambiguity and cryptic relatedness (see Figure S1).
Full text: Click here
Publication 2013
Birth Cohort CFC1 protein, human Childbirth DNA Replication Ethnicity Genome Genome-Wide Association Study Hydrocephalus, Normal Pressure Phenotype
To be classified as idiopathic PD, patients must meet the inclusion criteria proposed by the United Kingdom Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria (Hughes et al., 1992 (link)).
Patients who do not fulfill the proposed criteria will be classified as unspecified PD or as atypical PD based on the respective criteria. In the atypical PD subgroup, further classification will include subtypes, including PSP (Litvan et al., 1996 (link); Höglinger et al., 2017 (link)), MSA (Gilman et al., 2008 (link)), CBS (Boeve et al., 2003 (link)) or vascular parkinsonism (VP) (Zijlmans et al., 2004 (link)), based on internationally established criteria. All diagnostic classifications will be regularly updated. Patients with essential tremor are excluded from the patients group, and included into the control group. They may convert into typical PD and would then qualify for the inclusion into the patient group (Unal Gulsuner et al., 2014 (link); Laroia and Louis, 2011 (link)).
Patients with a secondary cause of parkinsonism (e.g., normal pressure hydrocephalus, toxic parkinsonism, medication-induced parkinsonism, symptomatic parkinsonism due to structural lesions) are excluded. Here, separation was based on established diagnostic criteria that include clinical symptoms as well as available clinical imaging results. Whereas normal pressure hydrocephalus may still be clinically over suspected (Espay et al., 2017 (link)), and presents with parkinsonism, gait disturbance, urinary symptoms, as observed for VP, the cardiovascular risk profile and the typical imaging findings with vascular lesions vs. symmetric enlargement of ventricles and diapedesis of CSF defines the difference of both secondary causes of parkinsonism (Rektor et al., 2018 (link)).
Full text: Click here
Publication 2018
Blood Vessel Brain Diagnosis Diapedesis Essential Tremor Heart Ventricle Hydrocephalus, Normal Pressure Hypertrophy Parkinson Disease Parkinsonian Disorders Patients Pharmaceutical Preparations Secondary Parkinson Disease Urine
Samples in the MIHG GWAS include individuals with PD collected by one of 13 ascertainment centers in the PD Genetics Collaboration (Scott et al. 2001 (link)) or by the Morris K. Udall Parkinson Disease Center of Excellence (J.M. Vance, PI) ascertainment core. These participants were recruited by participating movement disorder and neurology clinics, referrals, and advertisements. Unaffected spouse and friend controls were recruited when available and willing to participate. All participants provided written informed consent, in accord with protocols established by institutional review boards at each center.
All individuals with PD were examined by a board-certified neurologist. A neurological exam and standard clinical evaluation was performed on all participants with PD. Affected individuals exhibited at least two cardinal symptoms of PD, e.g. bradykinesia, resting tremor, and rigidity and no other causes of Parkinsonism or atypical clinical features. Unaffected individuals had no symptoms of PD upon physical examination and self-reported symptom questionnaire (Rocca et al. 1998 (link)). Individuals were excluded if there was a history of encephalitis, neuroleptic therapy within one year before diagnosis, evidence of normal pressure hydrocephalus, or a clinical course with unusual features suggesting atypical or secondary Parkinsonism. Additionally, a blood sample, family history, medical history, and standard cognitive test (Blessed Orientation Memory Concentration (BOMC) (Katzman et al. 1983 (link)) test or Modified Mini Mental Status exam (3MS) (Folstein et al. 1975 (link))) were obtained for each individual. To ensure diagnostic consistency across sites, clinical data for all participants were reviewed by a panel consisting of a board-certified neurologist with fellowship training in movement disorders, a board certified neurologist and medical geneticist, and a certified physician assistant.
Publication 2010
Antipsychotic Agents BLOOD Bradykinesia Cognitive Testing Diagnosis Encephalitis Ethics Committees, Research Fellowships Friend Genome-Wide Association Study Hydrocephalus, Normal Pressure Memory Mini Mental State Examination Movement Disorders Muscle Rigidity Neurologists Parkinson Disease Parkinsonian Disorders Physical Examination Physician Assistant Resting Tremor Secondary Parkinson Disease Spouse Therapeutics
Self-report variables relating to social factors that could be considered as deficits were identified separately in the CSHA and the NPHS (Table 1). Deficit selection was guided by two imperatives. First, we aimed to include a broad representation of factors that influence and describe an individual's social circumstance. These factors were based on previous studies which have suggested that they are relevant (e.g. social support, social engagement, sense of mastery/control over one's life circumstances).[1] (link)–[4] (link), [8] (link), [21] As part of a holistic description of social vulnerability, socioeconomic status (e.g. income adequacy, home ownership – addressing both wealth and housing security – and educational attainment) was also included,[22] (link), [23] (link) as these factors also influence vulnerability to insults with the potential to impact their health status. The two instrumental activities of daily living items included (ability to use the telephone and to get to places outside of walking distance) explicitly relate to an individual's ability to maintain social ties and participate in their community, and were therefore included in the social index. Second, working within the constraints of secondary data analysis, we aimed to make the measure of social vulnerability as sensible and as broadly applicable and comparable between datasets as possible.
Each respondent was assigned a score of 0 if a binary social deficit was absent and 1 if it was present; intermediate values were applied in cases of ordered response categories. For example, an individual scored 1 on the “lives alone” deficit if he/she reported living alone, and 0 if he/she did not. On the “do you ever feel you need more help” deficit, which had three response categories, possible scores were 0 if the answer was “never”, 0.5 for “sometimes” and 1 for “often”. As such, vulnerability on each deficit was mapped to the 0–1 interval. For each individual, a social vulnerability index was constructed using the sum of the deficit scores, yielding a theoretical range of 0–40 in the CSHA and 0–23 in the NPHS. To allow better comparison between the datasets, each with a different number of social deficits, the social vulnerability index was also calculated as a proportion of the total number of deficit items by dividing the sum of deficit scores by the number of deficits considered (40 in the CSHA and 23 in the NPHS), yielding an index with a theoretical range of 0–1.
Full text: Click here
Publication 2008
A-factor (Streptomyces) factor A Feelings Hydrocephalus, Normal Pressure Secure resin cement
Frailty was operationalized analogously to the social vulnerability index, in both the CSHA and NPHS, as described elsewhere.[17] (link), [24] (link) In brief, deficits representing self-reported symptoms, health attitudes, illnesses, and impaired functions (Table S1) were identified and given scores mapping to the 0–1 interval as described above, with a greater score corresponding to worse health status. The social vulnerability and frailty indices were mutually exclusive; no deficits overlapped.
Full text: Click here
Publication 2008
Hydrocephalus, Normal Pressure

Most recents protocols related to «Hydrocephalus, Normal Pressure»

Nineteen movement disorder patients who were being clinically evaluated and/or treated for either normal pressure hydrocephalus or Parkinson’s disease and 10 age-matched healthy control participants were enrolled over a period of 2 years from the Minneapolis VA Health Care System (MVAHCS) and University of Minnesota (UMN). Enrollment was designed to enroll a variety of types of movement disorder patients with varying gait dysfunction and postural instability ranging from normal gait and balance (MDS-UPDRS gait and pull test item scores of 0) to moderate dysfunction (MDS-UPDRS scores of 3). Patient participants were excluded if they were non-ambulatory or if they were unable to give consent. Control participants were excluded if they had any movement, gait, or balance disorders. Demographic information was collected (Table 1). This study was approved by the MVAHCS and UMN Institutional Review Boards, and all participants provided informed consent for participation according to the Declaration of Helsinki.
Full text: Click here
Publication 2023
Ethics Committees, Research Healthy Volunteers Hydrocephalus, Normal Pressure Movement Movement Disorders Patients
Between July 2019 and September 2021, a consecutive cohort of patients with PD visiting Chongqing University Jiangjin Hospital was prospectively recruited. This study was approved by the Ethical Committee of Chongqing University Jiangjin Hospital (JJ2020017029) and performed conforming to the guidelines of the Declaration of Helsinki, and all participants provided written informed consents.
The inclusion criteria were ① newly diagnosed patients with PD according to the UK Parkinson’s Disease Society Brain Bank clinical diagnostic criteria;18 (link) ② meeting de novo criteria, ie, L-dopa exposure no longer than 2 weeks and not within 4 weeks prior to study recruitment; ③ ranging from 40 to 85 years old. The exclusion criteria included ① medication-induced PD; ② signs or symptoms of progressive supranuclear palsy or multiple system atrophy according to consensus criteria;19 (link),20 (link) ③ known severe normal-pressure hydrocephalus (NPH) or vascular encephalopathy as demonstrated by MRI alone; ④ receiving drugs within the past 3 months that could influence serum Hcy, blood lipid and Cys C levels; ⑤ kidney and liver dysfunction; severe cardiovascular, respiratory, haematologic system, wasting or nutritional metabolism diseases. MRI and baseline cognitive evaluation were performed in all participants. Patients with PD dementia were excluded by clinical dementia rating (CDR) ≥ 0.5 points.
Publication 2023
BLOOD Blood Vessel Brain Cardiovascular System Cognition Dementia Diagnosis Encephalopathies Hydrocephalus, Normal Pressure Kidney Levodopa Lipids Metabolic Diseases Metabolism Multiple System Atrophy Nutrition Disorders Patients Pharmaceutical Preparations Progressive Supranuclear Palsy Respiratory Rate Respiratory System Serum
The systematic review began with the elaboration of the following clinical question: Is the treatment of normal pressure hydrocephalus using programmable valves more effective when compared to fixed pressure ones?
Publication 2023
Hydrocephalus, Normal Pressure Pressure
Individuals who were diagnosed as SCD were eligible for the study. Subjects who visited the hospital due to persistent cognitive worsening and were diagnosed with SCD after dementia work-ups are consecutively recruited. The dementia work up included detailed neuropsychological test battery, MRI, and routine blood sampling for syphilis, thyroid function, vitamin B deficiencies, and apolipoprotein epsilon genotyping. The inclusion criteria were as follows (Table 2): Age ≥ 60 years of age; Existence of persistent self-reported cognitive complaints; Normal performance (above −1.0 standard deviation [SD] of norms) on all subtests of neuropsychological test battery named Seoul Neuropsychological Screening Battery (SNSB);[4 ] Clinical dementia rating (CDR) score of 0;[5 ] Agreement to participate in the study and could visit the hospital for annual evaluations. The exclusion criteria were the following: Mild cognitive impairment (MCI) or dementia; Brain lesions known to cause cognitive impairment (tumor, stroke, or subdural hematoma); Any neurological disorders such as Parkinson’s disease, Huntington’s disease, epilepsy, or normal pressure hydrocephalus; Major psychiatric disorders such as uncontrolled depression, schizophrenia, alcoholism, or drug dependency; Abnormal blood laboratory findings such as abnormal thyroid function, low vitamin B12 or low folate, or positive syphilis serology, and; Hearing loss that is impossible to perform phone-based cognitive tests.
Full text: Click here
Publication 2023
Alcoholic Intoxication, Chronic Apolipoproteins BLOOD Brain Cerebrovascular Accident Cobalamins Cognition Cognitive Impairments, Mild Cognitive Testing Dementia Disorders, Cognitive Drug Dependence Epilepsy Folate Hearing Impairment Hematoma, Subdural Huntington Disease Hydrocephalus, Normal Pressure Major Depressive Disorder Neoplasms Nervous System Disorder Neuropsychological Tests Parkinson Disease Schizophrenia Syphilis Syphilis Serodiagnosis Thyroid Diseases Thyroid Gland Vitamin B Deficiency
Mice were purchased from the Jackson Laboratory (GSK-3βFL, Stock No 029592; NPHS-Cre, Stock No 008205), and the podocyte-specific GSK-3β-KO mice were generated as described previously [35 (link)]. The grouping and treatment protocols used in the aforementioned lncRNA Dlx6-os1 overexpression study with the db/m mice were adapted for this experiment.
Full text: Click here
Publication 2023
Hydrocephalus, Normal Pressure Mice, Laboratory Podocytes RNA, Long Untranslated Treatment Protocols

Top products related to «Hydrocephalus, Normal Pressure»

Sourced in United States, Germany, United Kingdom, China, Italy, Japan, France, Sao Tome and Principe, Canada, Macao, Spain, Switzerland, Australia, India, Israel, Belgium, Poland, Sweden, Denmark, Ireland, Hungary, Netherlands, Czechia, Brazil, Austria, Singapore, Portugal, Panama, Chile, Senegal, Morocco, Slovenia, New Zealand, Finland, Thailand, Uruguay, Argentina, Saudi Arabia, Romania, Greece, Mexico
Bovine serum albumin (BSA) is a common laboratory reagent derived from bovine blood plasma. It is a protein that serves as a stabilizer and blocking agent in various biochemical and immunological applications. BSA is widely used to maintain the activity and solubility of enzymes, proteins, and other biomolecules in experimental settings.
Hibernate A low is a cell culture reagent designed for the preservation and storage of cells. It maintains cell viability and preserves cellular functions during extended periods of refrigeration.
Sourced in United States
DNase I type IV is a laboratory enzyme that catalyzes the hydrolysis of DNA. It is a type of deoxyribonuclease that cleaves the phosphodiester bonds in the DNA backbone, effectively fragmenting the DNA molecule.
Sourced in United States, United Kingdom, Germany, Spain, France, Netherlands, Japan, China, Switzerland, Australia
Pyruvate is a key metabolite in cellular respiration and energy production. It serves as a critical intermediate in the tricarboxylic acid (TCA) cycle, also known as the Krebs cycle. Pyruvate is a versatile compound that can be converted into various other biomolecules, making it an important component in a wide range of biochemical processes.
Sourced in United States, Germany, United Kingdom, France, Switzerland, Canada, Australia, Japan, China, Belgium, Italy, Austria, Denmark, Spain, Netherlands, Sweden, Ireland, New Zealand, Israel, Gabon, India, Argentina, Macao, Poland, Finland, Hungary, Brazil, Slovenia, Sao Tome and Principe, Singapore, Holy See (Vatican City State)
GlutaMAX is a chemically defined, L-glutamine substitute for cell culture media. It is a stable source of L-glutamine that does not degrade over time like L-glutamine. GlutaMAX helps maintain consistent cell growth and performance in cell culture applications.
Sourced in United States, Germany, United Kingdom, China, France, Canada, Italy, Sao Tome and Principe, Japan, Switzerland, Macao, Israel, Australia, Spain, Austria, Sweden, Poland, Denmark, New Zealand, Belgium, Portugal, Ireland, Netherlands, Brazil, Colombia, India, Morocco, Argentina
Insulin is a lab equipment product designed to measure and analyze insulin levels. It provides accurate and reliable results for research and diagnostic purposes.
Sourced in United States, China, Japan
The ChemiDicTM XRS + Imaging System is a compact and versatile imaging device designed for a range of life science applications. It utilizes advanced imaging technologies to capture high-quality images of chemiluminescent, fluorescent, and colorimetric samples. The system provides a user-friendly interface and various imaging modes to accommodate different experimental requirements.
Sourced in Germany, United States, United Kingdom, France, Switzerland, Canada, Japan, Singapore, Italy
The ZEISS LSM 710 is a confocal laser scanning microscope. It enables high-resolution imaging of samples by using a focused laser beam to scan the specimen point-by-point, and then detecting the emitted fluorescence or reflected light. The microscope is designed to provide researchers with a versatile and reliable tool for a wide range of imaging applications.
Sourced in United States, China, Germany, United Kingdom, Italy, France, Canada, Australia, Belgium, Japan, Portugal, Sweden, Czechia, Switzerland, Spain
Image Lab software is a data analysis tool designed for use with Bio-Rad's gel and blot imaging systems. The software provides a user-friendly interface for capturing, analyzing, and processing images of gels, blots, and other samples.
Sourced in United States, China, United Kingdom, Germany, Canada, Japan, Morocco
Bax is a protein that plays a key role in the intrinsic apoptosis pathway. It is a member of the Bcl-2 family of proteins and functions as a pro-apoptotic regulator.

More about "Hydrocephalus, Normal Pressure"

Normal pressure hydrocephalus (NPH) is a neurological condition characterized by the abnormal accumulation of cerebrospinal fluid (CSF) within the ventricles of the brain, leading to increased intracranial pressure without ventricular enlargement.
This condition is distinct from communicating hydrocephalus, where the CSF flow is obstructed, and obstructive hydrocephalus, where there is a physical blockage in the CSF pathways.
NPH can result in a variety of neurological symptoms, including cognitive impairment, gait disturbances, and urinary incontinence.
These symptoms are often referred to as the 'classic triad' of NPH.
Accurate diagnosis and effective management of this condition are crucial, as it can be a treatable cause of dementia.
Researchers studying NPH may leverage the power of AI-driven protocol comparisons through PubCompare.ai to optimize their studies, enhance reproducibility, and improve the accuracy of their research.
This tool can help researchers locate the best protocols from literature, preprints, and patents, enhancing the reliability and effectiveness of their hydrocephalus and normal pressure investigations.
In the context of NPH research, researchers may also utilize bovine serum albumin (BSA) as a protein supplement, Hibernate A low as a cell culture medium, DNase I type IV to prevent DNA contamination, pyruvate as an energy source, GlutaMAX to support cell growth, insulin to regulate glucose metabolism, and the ChemiDic™ XRS + Imaging System and LSM 710 confocal microscope for imaging and analysis.
The Image Lab software may also be employed for data processing and visualization.
Additionally, the pro-apoptotic protein Bax may be studied in relation to cell death processes associated with NPH.
By leveraging these tools and techniques, researchers can advance our understanding of the pathophysiology, diagnosis, and treatment of normal pressure hydrocephalus, ultimately improving the care and outcomes for patients affected by this condition.